Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Splinting vs Exercise in De Quervain's Tenosynovitis

NCT06995534 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-05-29
Last updated
2026-03-24

Condition(s) studied

SplintsExercise TherapyDe Quervains TenosynovitisPain ManagementUltrasonographic

Investigational drug(s) / intervention(s)

splintExercise Therapy

splint: static wrist-hand splint + education on activity modification and positioning in daily life

Exercise Therapy: Home-based Exercise Therapy + Education on activity modification and positioning in daily life

Study summary

De Quervain's disease is a painful tenosynovitis of the abductor pollicis longus and extensor pollicis brevis muscle tendons located in the first dorsal compartment. The primary treatment for De Quervain's disease is conservative; surgical intervention is rarely required. Currently, there is no standardized treatment protocol supported by strong, up-to-date evidence.

The aim of this study is to compare the effectiveness of a static hand-wrist resting splint and exercise therapy in the conservative treatment of De Quervain's tenosynovitis. Patients will be evaluated in terms of pain levels, functional/symptom status, hand-finger strength, pressure pain threshold (PPT), tendon cross-sectional area measured by ultrasound, and the presence of effusion findings (semiquantitative; 0-3), and patient satisfaction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged between 18 and 65 years Patients experiencing wrist pain and tenderness for less than 3 months and clinically diagnosed with acute or subacute De Quervain's tenosynovitis Visual Analog Scale (VAS) pain score ≥ 3 Exclusion Criteria: * History of trauma Wrist fractures Local infection Presence of rheumatologic diseases (e.g., rheumatoid arthritis, psoriatic arthritis) Presence of symptomatic hand osteoarthritis Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids Receipt of physical therapy for the hand or wrist within the past 3 months Corticosteroid injection into the hand or wrist within the past 3 months Diagnosed with significant neurological disorders (e.g., upper motor neuron disease) Presence of uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus, congestive heart failure, chronic kidney disease, hepatic failure) Major psychiatric disorders Communication difficulties

Primary outcome measure(s)

  • VAS pain — baseline, week 2 and week 6
    VAS pain activity and rest: 0 no pain; 10 unbearable/max. pain.
  • Patient Rated Wrist Evaluation( PRWE) — baseline, week 2 and week 6
    The Patient-Rated Wrist Evaluation (PRWE) is a brief and effective self-report questionnaire that allows patients to assess their own wrist and hand problems. The PRWE consists of two main subscales: the Pain Subscale (0-50 points) and the Function Subscale (0-50 points). The total score ranges from 0 (no disability) to 100 (maximum pain and functional impairment).
  • The Disabilities of the Arm, Shoulder and Hand (DASH) — baseline, week 2 and week 6
    The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a self-reported outcome measure used to assess the impact of upper extremity disorders on daily activities. It consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform). The total score ranges from 0 to 100, where 0 indicates no disability and 100 indicates severe functional limitation.

Trial sites (1)

FacilityCityRegionStatus
Konya Beyhekim Training and Research Hospital Konya Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06995534 on ClinicalTrials.gov ↗ ← All trials in Turkey